DaVita Inc.

DVA Healthcare Medical Care Facilities

DaVita Inc.’s revenue for fiscal 2025 (year ended December 2025) was $13.6 billion, up 6.46% from fiscal 2024.

Revenue
+4.62%
EPS
+67.0%
Free cash flow
−45.8%
Total debt
+5.07%

Quarter to September 2026, against a year earlier

189.65 5.17 −2.65%
Market cap
$12.3B
P/E
14.0×
Fwd P/E
13.0×
Dividend yield
—
F-score
6/9
Altman Z
1.49
Beneish M
−2.59
Dividend safety
n/a

DaVita Inc. 10-Q filed Oct 29, 2026

Fiscal Q3 2026 · Period ended Sep 30, 2026 · Filed · accepted 5:03 PM ET · Document on sec.gov · Filing index

Red flags

  • Impairment

    DaVita Inc. recorded a goodwill impairment of $57.1 million in fiscal Q3 2026

    10-Q filed · The filing · sec.gov

What changed

Part I, Item 2, Management’s Discussion and Analysis, against the 10-Q filed Aug 4, 2026: 8 added · 4 removed · 39 modified; 16 with only figures updated

  1. Modified · Forward-looking statements

    •external conditions, including those related to general economic, political and global health conditions, including without limitation, the impact of global events and political or governmental volatility, including in the Middle East and Ukraine; the impact of the domestic political environment and related developments on the current healthcare marketplace, our patients and on our business; the impact of infectious diseases or other adverse conditions on our financial condition, the chronic kidney disease population and our patient population; supply chain challenges and disruptions, including without limitation with respect to certain key services, critical clinical supplies and equipment we obtain from third parties, and including any impacts on our supply chain and cost of supplies as a result of global events, natural disasters or evolving trade policies, including tariffs; the impact on our patients and industry of continued increased competition from dialysis providers and others, including new or potential entrants in the dialysis and pre-dialysis marketplace; the impact of new or innovative technologies, drugs, or other treatments, including our ability to successfully implement new technologies, treatments or therapies in our business such as those related to middle molecule toxin clearance; elevated teammate turnover or labor costs; and our ability to respond to challenging U.S. and global economic and marketplace conditions, including, among other things, our ability to successfully identify cost saving opportunities and execute on related strategic initiatives;

50 more changes in this Item, word by word, in Powerpack.